Navigation Links
ARIUS Announces Third Quarter Fiscal 2007 Financial Results
Date:10/12/2007

d CD63 antibody program continues to produce results from further preclinical studies in a variety of cancer indications in its progress towards human clinical trials.

Takeda Collaboration

ARIUS successfully met its year one obligations and received all scheduled research payments from Takeda.

Additional Product Updates

Additionally, ARIUS continues to progress several other antibody candidates and has antibody programs targeting the MCSP antigen, AR005 antigen, and 37LRP in addition to several other undisclosed programs.

Management Change:

As part of its corporate governance review, ARIUS' Board of Directors has decided to nominate Mr. Carl Gordon as non-executive Chair of the Board of Directors. Dr. Young remains as President and Chief Executive Officer of the Company.

During the quarter, ARIUS' Executive Vice President and Chief Business Officer, Helen Findlay, left the Company to pursue other opportunities. In Ms. Findlay's role, she contributed to ARIUS' partnering and financing activities, helping to establish ARIUS on the path to becoming a clinical company.

Financial Results:

All amounts are in Canadian dollars unless otherwise indicated.

For the nine-month period ended August 31, 2007, the Company recorded a net loss of $8,104,701 ($0.18 per share) compared to a net loss of $2,820,462 ($0.09 per share) for the same period in fiscal 2006. The increase in net loss was the result of lower revenue, higher research and development expenses and higher general and administrative costs offset partially by lower interest expense and higher interest income. For the three-month period ended August 31, 2007, the Company recorded a net loss of $2,761,874 ($0.06 per share) compared to a net loss of $1,469,728 ($0.03 per share) for the three-month period ended August 31, 2006. This increase in net loss for the three-month period is primarily the result of higher research and development expenses, higher general
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Streptococcus salivarius
2. Streptococcus salivarius
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 29, 2015 GeneWEAVE, ... organisms (MDROs), announced that initial feasibility data supporting ... detection and susceptibility testing from positive blood cultures ... May 31, 2015 in New Orleans, LA. The ... molecular diagnostics that can quickly detect bacteria and ...
(Date:5/29/2015)... 2015 The Academy of Model Aeronautics ... school graduates from across the nation. , The Academy ... qualified AMA Youth Members with scholarships to pursue technical ... Program has awarded nearly $900,000 to college-bound aero-modelers. The ... organizations and individuals, AMA member donations, a portion of ...
(Date:5/29/2015)... Asthma treatment could   see significant ... enter arena, says   GBI Research ... of the leading asthma brands, such as Advair (fluticasone ... global market for asthma treatment is set to witness ... New analysis from business intelligence provider GBI ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Market ... (Chem-Report ) signed a partnership agreement for quality ... authorised to distribute and sell research reports worked ... at Partners Department, commented upon the agreement: “Chem-Report ... on key petroleum and chemical markets on global ...
Breaking Biology Technology:Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3Academy of Model Aeronautics Awards $46,500 in Scholarships to College-Bound Model Aviation Pilots 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3
... of... -- CAMBRIDGE, Massachusetts, August 26, 2010 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
... New York State Department of Health has licensed Genelex Corporation,s ... state. The issued Clinical Laboratory Permit is for DNA testing ... 50 percent of the most commonly prescribed medicines. Research shows ... the genetic coding for these enzymes, greatly increasing their risk ...
... CFO -- LONDON, August 26, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 2Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 3Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 4Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 5Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 6Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 7Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 8Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 9New York State Licenses Personalized Prescribing DNA Tests 2Hikma - Half Year Results Interviews With CEO and CFO 2Hikma - Half Year Results Interviews With CEO and CFO 3Hikma - Half Year Results Interviews With CEO and CFO 4Hikma - Half Year Results Interviews With CEO and CFO 5
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
(Date:5/28/2015)... , May 28, 2015 Industry analyst ... a new report titled "Markets for Self-Healing Materials: ... inorganic capsule and vascular systems, biomaterials, relevant shape ... to around $2.7 billion by 2020. ... extensive coverage of smart materials. Other recent n-tech reports ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... Ill. (June 18, 2012) Seeking to solve some ... source facilities at national research laboratories in the United ... Canadian Light Source and the Advanced Photon Source (APS) ... Laboratory agreed in January 2012 to a Partner User ...
... , PHILADELPHIA Healthy humans harbor an enormous and ... within their intestines. These microbial partners provide beneficial aid ... the development of a healthy immune system. In a ... , David Artis, PhD, associate professor of Microbiology, and ...
... to the simple sponge to find clues about the evolution ... a mechanism that coordinates the expression of genes that lead ... of the animal world may not be so distant after ... network," are published in the Proceedings of the National ...
Cached Biology News:Advanced Photon Source and Canadian Light Source strengthen ties 2Brothers in arms: Commensal bacteria help fight viruses 2Clues to nervous system evolution found in nerve-less sponge 2